Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125215641 | 12521564 | 1 | I | 20141103 | 20141110 | 20160701 | 20160701 | EXP | US-ASTRAZENECA-2014SE89825 | ASTRAZENECA | 55.00 | YR | M | Y | 0.00000 | 20160701 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125215641 | 12521564 | 1 | PS | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 1 | Oral | Y | U | 0 | 10 | MG | TABLET | QD | |||||
| 125215641 | 12521564 | 2 | SS | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 1 | Oral | Y | U | 0 | 10 | MG | TABLET | QD | |||||
| 125215641 | 12521564 | 3 | SS | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 1 | Oral | Y | U | 0 | 10 | MG | TABLET | QD | |||||
| 125215641 | 12521564 | 4 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | U | U | 0 | 80 | MG | QD | ||||||
| 125215641 | 12521564 | 5 | C | DIOVAN | VALSARTAN | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 6 | C | METOPROLOL. | METOPROLOL | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 7 | C | ACETYLSALICYLIC ACID | ASPIRIN | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 8 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 9 | C | EFIENT | PRASUGREL HYDROCHLORIDE | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 10 | C | ACETYLCYSTEINE. | ACETYLCYSTEINE | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 11 | C | NITROLINGUAL | NITROGLYCERIN | 1 | Sublingual | U | 0 | ||||||||||
| 125215641 | 12521564 | 12 | C | PANTALOC | 2 | Oral | U | 0 | |||||||||||
| 125215641 | 12521564 | 13 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 14 | C | DIAMICRON | GLICLAZIDE | 1 | Oral | U | 0 | ||||||||||
| 125215641 | 12521564 | 15 | C | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | U | 0 | ||||||||||
| 125215641 | 12521564 | 16 | C | ROSUVASTATIN. | ROSUVASTATIN | 1 | Oral | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125215641 | 12521564 | 1 | Type 2 diabetes mellitus |
| 125215641 | 12521564 | 2 | Type 2 diabetes mellitus |
| 125215641 | 12521564 | 3 | Type 2 diabetes mellitus |
| 125215641 | 12521564 | 4 | Diuretic therapy |
| 125215641 | 12521564 | 5 | Hypertension |
| 125215641 | 12521564 | 6 | Hypertension |
| 125215641 | 12521564 | 7 | Prophylaxis |
| 125215641 | 12521564 | 8 | Hypertension |
| 125215641 | 12521564 | 9 | Prophylaxis |
| 125215641 | 12521564 | 10 | Product used for unknown indication |
| 125215641 | 12521564 | 11 | Chest pain |
| 125215641 | 12521564 | 12 | Erosive oesophagitis |
| 125215641 | 12521564 | 13 | Diabetes mellitus |
| 125215641 | 12521564 | 14 | Diabetes mellitus |
| 125215641 | 12521564 | 15 | Diabetes mellitus |
| 125215641 | 12521564 | 16 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125215641 | 12521564 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125215641 | 12521564 | Acute kidney injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125215641 | 12521564 | 1 | 20140122 | 20141022 | 0 | |
| 125215641 | 12521564 | 2 | 20141029 | 20141105 | 0 | |
| 125215641 | 12521564 | 3 | 20141110 | 0 | ||
| 125215641 | 12521564 | 4 | 20141021 | 20141104 | 0 |